Holen Sie sich die Stockscreener-App
3.85
3.02%
-0.12
Handel nachbörslich:
3.75
-0.10
-2.60%
Schlusskurs vom Vortag:
$3.97
Offen:
$3.9
24-Stunden-Volumen:
292.34K
Relative Volume:
3.14
Marktkapitalisierung:
$126.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.46M
KGV:
-9.1275
EPS:
-0.4218
Netto-Cashflow:
$-34.00M
1W Leistung:
-15.01%
1M Leistung:
+5.19%
6M Leistung:
-73.72%
1J Leistung:
-81.67%
1-Tages-Spanne:
$3.80
$4.10
1-Wochen-Bereich:
$3.69
$4.64
52-Wochen-Spanne:
$3.35
$21.92
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Firmenname
Contineum Therapeutics Inc
Sektor
Branche
Telefon
(858) 333-5280
Adresse
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Vergleichen Sie CTNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
3.85 | 126.25M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-22 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-30 | Eingeleitet | Stifel | Buy |
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum initiated with an Outperform at William Blair - TipRanks
Bank of America Corp DE Increases Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
13,307 Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) Acquired by Nuveen Asset Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Deutsche Bank AG Purchases New Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Northern Trust Corp Increases Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics ATM - Leerink Partners
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook By Investing.com - Investing.com South Africa
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook - Investing.com
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $20.00 at Morgan Stanley - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Earns Outperform Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference - BioSpace
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum Therapeutics May 2025 slides: Multiple shots on goal with 2H25 catalysts ahead - Investing.com India
Barclays PLC Buys 7,978 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Wells Fargo & Company MN Raises Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (CTNM) Expected to Announce Earnings on Thursday - Defense World
(CTNM) Investment Analysis - news.stocktradersdaily.com
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
JPMorgan Chase & Co. Has $416,000 Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., As Chief Medical Officer - citybiz
Geode Capital Management LLC Purchases 59,732 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - BioSpace
Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development - marketscreener.com
Form 8-KCurrent report - ADVFN
Critical Contrast: Contineum Therapeutics (CTNM) and Its Rivals - Defense World
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate - Yahoo Finance
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
(CTNM) On The My Stocks Page - news.stocktradersdaily.com
Contineum Therapeutics (CTNM) vs. Its Competitors Head-To-Head Survey - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from Analysts - Defense World
Contineum Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Contineum Therapeutics Rings the Closing Bell - Nasdaq
How the (CTNM) price action is used to our Advantage - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Charles Schwab Investment Management Inc. Buys 12,035 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - The AM Reporter
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Finanzdaten der Contineum Therapeutics Inc-Aktie (CTNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Contineum Therapeutics Inc-Aktie (CTNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer |
Nov 18 '24 |
Sale |
16.38 |
6,190 |
101,421 |
169,572 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):